Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Neurofibromatosis type 2 Indication Strategy Report 2026: merlin, Trials and Deals
21 July 2026
Neurofibromatosis type 2 indication strategy report covering epidemiology, merlin biology, active trials, competition and deal signals using PatSnap MCP evidence.
8 min read
DDX28 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX28, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX27 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX27, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX25 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX25, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX24 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX24, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX23 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX23, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX20 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX20, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX19B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX19B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX19A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX19A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX18 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX18, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DDX11 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DDX11, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Neurofibromatosis type 1 Indication Strategy Report 2026: MEK1, Trials and Deals
21 July 2026
Neurofibromatosis type 1 indication strategy report covering epidemiology, MEK1 biology, active trials, competition and deal signals using PatSnap MCP evidence.